Asset Details
Do you wish to reserve the book?
The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively
Do you wish to request the book?
The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively
2021
Overview
Introduction Traditional cancer therapy has many disadvantages such as low selectivity and high toxicity of chemotherapy, as well as insufficient efficacy of targeted therapy. To enhance the cytotoxic effect and targeting ability, while reducing the toxicity of antitumor drugs, an antibody drug conjugate (ADC) was developed to deliver small molecular cytotoxic payloads directly to tumor cells by binding to specific antibodies via linkers. Method By reviewing published literature and the current progress of ADCs, we aimed to summarize the basic characteristics, clinical progress, and challenges of ADCs to provide a reference for clinical practice and further research. Results ADC is a conjugate composed of three fundamental components, including monoclonal antibodies, cytotoxic payloads, and stable linkers. The mechanisms of ADC including the classical internalization pathway, antitumor activity of antibodies, bystander effect, and non‐internalizing mechanism. With the development of new drugs and advances in technology, various ADCs have achieved clinical efficacy. To date, nine ADCs have received US Food and Drug Administration (FDA) approval in the field of hematologic tumors and solid tumors, which have become routine clinical treatments. Conclusion ADC has changed traditional treatment patterns for cancer patients, which enable the same treatment for pancreatic cancer patients and promote individualized precision treatment. Further exploration of indications could focus on early‐stage cancer patients and combined therapy settings. Besides, the mechanisms of drug resistance, manufacturing techniques, optimized treatment regimens, and appropriate patient selection remain the major topics. Antibody drug conjugate (ADC) has been under rapid development in recent years, the application of ADC has changed traditional treatment patterns for pan‐cancer patients and has become a great breakthrough for individualized precision treatment. We conducted this review to summarize basic characteristics, clinical progress, and challenges of ADCs to provide a reference for clinical practice and further researches.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
/ Antibodies, Monoclonal - therapeutic use
/ Antigens
/ Antigens, Neoplasm - immunology
/ cancer
/ DNA
/ Hematologic Neoplasms - immunology
/ Hematologic Neoplasms - therapy
/ Humans
/ Immunoconjugates - immunology
/ Immunoconjugates - therapeutic use
/ Leukemia
/ Lymphoma
/ Molecular Targeted Therapy - methods
/ Pancreatic Neoplasms - therapy
/ Patients
/ Payloads
/ Review
/ therapy
/ Tumors
